Bone metastasis is common in patients with advanced malignant tumor. According to the statistics, each year millions of tumor patients especially patients with breast cancer, prostate cancer and lung cancer suffer from bone metastasis around the world. Bone metastasis of malignant tumor often result in severe lesions in bone including such skeletal-related events as bone pain, pathological fracture, spinal cord compression and hypercalcemia. Once Bone metastasis occurs, most patients will suffer from different degrees of pain even pathological fracture, which will obviously influence their life quality.
The most common drug for bone metastasis is diphosphonate. Three generations of diphosphonate, respectively, etidronate and clodronate representated by Bonefos, pamidronate and alendronate sodium represented by Bonin as well as sodium ibandronate and zoledronic acid are now used in the clinic.
View Full Report at: http://www.marketresearchreports.biz/analysis/294392
First registered and used in the clinic under the trade name of Bondronat in Germany and Austria in 1996, sodium ibandronate was approved by FDA to come into the market as a daily treatment of osteoporosis under the trade name of Boniva. However, since drug makers later developed more convenient dose, Boniva has not appeared in the American market until FDA approved its monthly use in 2005.
The number of new cases of cancer is over 3 million each year in China, among which about 50% suffer from bone metastasis. In 2001, some local enterprises began to apply for relevant products of sodium ibandronate and succeeded in 2002. In Jul. 2006, sodium ibandronate produced by Roche entered China under the trade name of Bondronat. Since then, sodium ibandronate has developed fast, annual sales value rising from CNY 50.38 million in 2010 to CNY 87.23 million in 2014 and CAGR during this period reaching up to 14.71%. sodium ibandronate enjoys a vast demand in China. Currently, sodium ibandronate market in China is mainly occupied by the following companies: Science & Technology General Company Hebei Medical University, Roche Diagnostics GmbH GE), Hencer Pharmacy and Easton Pharmaceutical Co., Ltd, among which Science & Technology General Company Hebei Medical University has the largest market share of about 58% for sales value in 2014.
With the degradation of environmental pollution and the ageing population, the number of new cases of cancer each year is expected to keep increasing, which shall boost the growth of sodium ibandronate market in China.
Download Detail Report With Complete TOC at: http://www.marketresearchreports.biz/sample/sample/294392
Readers can get at least the following information from this report:
market size of sodium ibandronate in China
competitive landscape of sodium ibandronate in Chinese market
price of sodium ibandronate made by different enterprises in China
market outlook of sodium ibandronate in China
The author suggests the following groups of people purchase this report:
manufacturers of anti-tumor drugs
investors/ research institutions interested in Chinese medicine market
any interest in the Chinese medicine market, please contact CRI for customized survey service
Browse all latest Articles of Market Research Reports
MarketResearchReports.biz is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save time and money for our clients.
We are a one stop solution for all your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting services. We serve all sizes and types
of companies spanning across various industries.
Browse Our Press Releases by Prnewswire:
Browse More PressRelease:
90 Sate Street, Suite 700
Albany, NY 12207
USA: Canada Toll Free: 866-997-4948